Ligand制药 LGND 深 沪
已收盘 10-31 16:00:00 美东时间
191.31
+4.250
+2.27%
华盛通- 最 高192.83
- 今 开187.78
- 成交量 38.32万股
- 最 低 186.45
- 昨 收 187.06
- 总市值 37.29亿
- 52周最高 194.44
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 93.58
- 委 比 76.81%
- 总股本 1949.45万
- 历史最高 248.6071
- 量 比 2.88
- 振 幅 3.41%
- 历史最低 -19.8529
- 每 手 1
- 风险率 25.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ligand to Participate in November Investor Conferences
Ligand Pharmaceuticals announced that CEO Todd Davis and CFO Tavo Espinoza will participate in three upcoming investor conferences: the UBS Global Healthcare Conference in Palm Beach Gardens on November 10, the Stifel 2025 Healthcare Conference in New York on November 12 at 8:40 a.m. ET, and the Southwest IDEAS 2025 Investor Conference in Dallas on November 20 at 1:20 p.m. CT. Management will host one-on-one meetings and presentations, and invest...
10-30 20:01
Ligand to Host Investor Day on December 9, 2025
Ligand Pharmaceuticals will hold its Investor Day on December 9, 2025, at The Harvard Club in New York City, featuring presentations by CEO Todd Davis, CFO Tavo Espinoza, and senior management. Topics include the company’s strategy, investment activity, royalty portfolio, and financial outlook. Scott Plesha of Pelthos Therapeutics will discuss the recent launch of ZELSUVMI™ for molluscum contagiosum. A live webcast and replay will be available on...
10-16 11:00
Ligand's Captisol Technology Powers New FDA-Approved Lasix ONYU for At-Home Edema Treatment in Heart Failure Patients
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner SQ Innovation Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Lasix® ONYU (furosemide injection), a
10-09 19:16
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
Ligand Pharmaceuticals and SQ Innovation announced FDA approval of Lasix ONYU, a novel high-concentration furosemide injection for treating edema in chronic heart failure patients. This subcutaneous treatment can be self-administered at home, offering a cost-effective alternative to hospital-based IV diuretic therapy. Lasix ONYU uses Captisol technology, enhancing drug solubility and stability, and is designed to reduce hospitalizations, benefiti...
10-09 11:00
Arecor And Ligand Pharmaceuticals Sign Royalty And Technology Access Deal For AT220 And AT292 Worth Up To $11M
Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 millionAT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in
09-25 14:54
Ligand Pharma Amends Credit Agreement for Stability
Ligand Pharma ( ($LGND) ) has shared an update. On September 12, 2025, Ligand P...
09-17 05:50
What Analysts Are Saying About Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals (NASDAQ:LGND) has been analyzed by 4 analysts in the las...
09-03 06:01
美股大行评级 | 英伟达、Snowflake、Five Below、Pure Storage等公司获多家大行集体上调目标价
今日重点评级关注：摩根大通：维持Futu Holdings"超配"评级，目标价从200美元升至270美元；Craig-Hallum：维持英伟达"买入"评级，目标价从195美元升至245美元
08-29 09:47
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $206
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $157 to $206.
08-29 00:34
Ligand to Participate in September Investor Conferences
Ligand Pharmaceuticals' CEO Todd Davis and CFO Tavo Espinoza will attend the Citi 20th Annual BioPharma Conference in Boston on September 3, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9, 2025. Management will engage in fireside chats and presentations, and host one-on-one investor meetings. Investors should contact Citi or H.C. Wainwright representatives for meeting arrangements. For more infor...
08-19 20:00
